Device Industry Hopes Trump’s FDA Nominee Will Support Medtech Innovation

 
• By Sarah Karlin-Smith

Martin Makary’s ties to a compounder and telehealth company offering compounded GLP-1s may concern the drug industry and raise questions about his fundamental beliefs in the FDA’s role regulating drug manufacturing.

FDA building.
Approval marks Hyloris' second in the US this year after Maxigesic IV • Source: Shutterstock

More from Medtech Insight

More from Regulation